drugset / Trial / NCT03614858
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
Phase 1/2
Unknown
20 enrolled
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
The First Affiliated Hospital of Soochow University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, open-label ,phase 1/2 study to evaluate the safety and efficacy of targeted CD19/CD22 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19/CD22 positive Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
Timeline
- Start
- 2017-09-01
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tisagenlecleucel | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | Tisagenlecleucel | Cell therapy | 2e+07 cells/kg | Intravenous |